ICPT News and Press, Intercept Pharmaceuticals Inc. From 04/27/23

2023-04-27 15:49:00 ET Shares of the non-viral liver disease specialist Intercept Pharmaceuticals (NASDAQ: ICPT) are under heavy pressure today. Specifically, the drugmaker's stock was down by 9.7% on exceptionally high volume as of 3:02 p.m. ET Thursday afternoon. The big loss ...

2023-04-27 14:24:02 ET Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Conference Call April 27, 2023, 8:00 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President and Chief Executive Officer Dr. Michell...

2023-04-27 13:52:44 ET For further details see: Intercept Pharma off 11% on Q1 misses

2023-04-27 10:01:57 ET Gainers: ContraFect ( CFRX ) +112% . Accuray ( ARAY ) +14% . Mainz Biomed ( MYNZ ) +15% . Mangoceuticals ( MGRX ) +14% . Immix Biopharma ( IMMX ) +9% . Losers: Baudax Bio ( BXRX ) -52% ....

2023-04-27 07:08:21 ET Intercept Pharma press release ( NASDAQ: ICPT ): Q1 GAAP EPS of -$0.77 misses by $0.15 . Revenue of $68M (+14.9% Y/Y) misses by $4.68M . For further details see: Intercept Pharma GAAP EPS of -$0.77 misses by $0.15, revenue of $68M m...

Ocaliva® net sales of $68.0 million, representing 15% growth over the prior year quarter Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting set for May 19, 2023, to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH; PDUFA Target Action Date ...

Seven abstracts in primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) accepted at EASL 2023 Accepted abstracts include podium presentation of new data from the planned interim analysis of a Phase 2 study of investigational combination of obeticholic ac...

2023-04-26 12:02:15 ET Intercept Pharma ( NASDAQ: ICPT ) is scheduled to announce Q1 earnings results on Thursday, April 27th, before market open. The consensus EPS Estimate is -$0.60 (-3.4% Y/Y) and the consensus Revenue Estimate is $72.68M (-17.9% Y/Y). Over the last...

2023-04-25 13:50:22 ET Summary Obeticholic acid (OCA) has shown potential for treating NASH with fibrosis, demonstrating improvements in liver histology, inflammation, and steatosis. Safety concerns, including liver injury and worsening cardiometabolic risk factors, raise doubts a...

MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financia...